Option chain shows key data for Novonesis (Novozymes) B's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Novonesis (Novozymes) B.

Novonesis (Novozymes) B (OTC:NVZMF) Stock, Option Chain

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

News

Intraday Update

Markets

Movers

Trading Ideas

AAXN

ABLZF

ACDSF

ACLS

ACRE

ADBE

ADCOF

ADNT

ADSK

ADYEY

AGNC

AIQUY

ALEC

ALFVY

ALLE

AMED

AMRC

AMZN

ANSS

APAM

APPF

ARES

ASML

ASPU

BCPC

BESIY

BFAM

BFST

BKOR

BMRMF

BROG

BTAI

BTDPY

BXMT

CBSH

CCLAY

CCOEY

CCXI

CDAY

CERN

CGEN

CHDN

CIFAF

CLPBF

CLPBY

CNSWF

CPRT

CSGP

CTAS

DDOG

DOCU

DOOO

DPDW

DSGX

ENAKF

ENBP

ENPH

EPAM

Eaton Vance Tax-Advantaged Global Dividend

Stocks That Hit 52-Week Highs On Wednesday

AAON

ADYYF

ALPMY

APLT

APTO

ATBPF

CHTR

CLHRF

CNNE

CPSH

CRMT

CVCO

CWST

DECK

DXCM

EDPFY

ELVT

EPRT

FATE

Flaherty Crumrine/Claymore Preferred Securities

FJTSY

FLEX

FORTY

FTMNF

GLDLF

GLPI

GLVMF

HNNMY

INVH

ITCC

ITMR

KDDIY

LBRDA

LBRDK

LJUIF

LLIT

MCBI

MCRI

MDLZ

MGEE

MGRUF

Blackrock Muniholdings New York Quality Fund

MKTAY

MLKKF

MSCI

Blackrock Muniholdings California Quality Fund

NDAQ

Nuveen Insured Tax-Free Advantage Municipal Fund

Nuveenn Intermediate Duration Quality Municipal Term Fund Common Shares of Beneficial Interest

Nuveen Georgia Dividend Advantage Municipal Funds 2

Nuveen Insured California Tax-Free Advantage Municipal Fund

Nuveen Municipal High Income Opportunity Fund

Stocks That Hit 52-Week Highs On Friday

AAPL

ADGS

AEBZY

AFBA

AFGC

AGRX

AGYS

AKAM

ALMFF

AMAT

APMCF

ASAZY

ATLC

AUBN

AVGO

AZUL

BABYF

BAESF

BF-B

BMDPY

BUROF

BYDIF

CABO

CACI

CDPYF

CELH

CFBK

CFFA

CGEMY

CGNX

CHGCY

CLNXF

CMWAY

COHU

COST

CPWHF

CSLLY

CSPI

CWCO

DASTY

DBOEF

DCMYY

DEAC

DNNGY

DOGEF

Novonesis (Novozymes) B

JP Morgan downgrades Novozymes (OTC:<a class="ticker" href="/stock/NVZMF#OTC">NVZMF</a>) from Neutral to Underweight.

Downgrades

Analyst Ratings

NVZMF

JP Morgan Downgrades Novozymes to Underweight

Merck KGaA (<a href="http://www.zacks.com/stock/quote/MKGAF">MKGAF</a>) recently announced its plans to divest its Crop BioScience business to Denmark based Novozymes A/S (<a href="http://www.zacks.com/stock/quote/NVZMF">NVZMF</a>) for $275 million. Crop BioScience, which researches, develops and commercializes technologies to improve plant health and crop yields, is a part of Merck KGaA's Performance Materials division.

	The companies expect the transaction to close in early 2011.

	The Crop BioScience business generated revenues of about €35 million in fiscal 2009, through three dedicated legal entities in North and South America – EMD Crop BioScience, Milwaukee, USA; EMD Crop BioScience Canada; and Merck Crop BioScience Argentina.

	Crop BioScience's products include Optimize and Torque IF, which contain LCO Promoter Technology - a naturally-occurring molecule that brings extraordinary early-season vigor and plant health benefits to a number of crops. The Crop BioScience business became a part of Merck KGaA with the acquisition of Lipha in 1991. Additionally, the business got expanded with the acquisition of Agribiotics in 2006.

	We currently have a Zacks #3 Rank (short-term Hold rating) on Merck KGaA. We are of the opinion that the acquisition of Millipore should help reduce the company's dependence on the pharmaceutical and liquid crystals sector and help build its specialty chemicals and performance life sciences portfolio. Further, with the divestment of the Crop BioScience business, Merck KGaA will be able to fully concentrate on life science, as the Crop BioScience business is focused on a specific segment within the agricultural industry, which has almost no relevance to the company's other business parts.
   <a href="http://www.zacks.com/">Zacks Investment Research</a>

MKGAF

MKGAF Sells Agricultural Business - Analyst Blog

Comments

Novonesis (Novozymes) B

Novonesis (Novozymes) B (NVZMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga